INBX
NASDAQ
$84.09
Inhibrx Biosciences Inc (INBX)
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $277.50 (+230.00%)
Market Cap
$1.33B
Free Cash Flow Yield
-9.90%
Beta (5Y)
1.39
Price Chart
Valuation
Market Cap$1.33B
P/S1029.47
P/B212.28
Profitability
Total Revenue (TTM)$1.30M
Gross Profit (TTM)-$100M
EBITDA-$121M
Operating Margin-9465%
EPS-$8.95
Financial Health
Debt-to-Equity-831.9%
Free Cash Flow Yield-9.90%
Growth & Risk
Beta (5Y)1.39
Sharpe Ratio1.44